Regulus Therapeutics Inc.
RGLS
Rank in Stocks
#17341
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Share Price
$8.16
Last synced: 2025-06-26
Market Cap
$234.57M
Change (1 day)
0.00%
Change (1 year)
-56.96%
Country
US
Trade Regulus Therapeutics Inc. (RGLS)
Category
Healthcare
P/E ratio for Regulus Therapeutics Inc. (RGLS)
P/E ratio as of October 2026 TTM: -12.22
According to Regulus Therapeutics Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -12.22. At the end of 2022 the company had a P/E ratio of -3.02.
P/E ratio history for Regulus Therapeutics Inc. from 2002 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -12.22 | 88.66% |
| 2023 | -6.48 | 114.24% |
| 2022 | -3.02 | 40.57% |
| 2021 | -2.15 | -106.89% |
| 2020 | 31.22 | -179.99% |
| 2019 | -39.03 | -20.73% |
| 2018 | -49.23 | 35.47% |
| 2017 | -36.34 | -16.96% |
| 2016 | -43.76 | -125.74% |
| 2015 | 170.01 | -123.46% |
| 2014 | -724.66 | -613.57% |
| 2013 | 141.10 | -85.48% |
| 2012 | 971.67 | 7.38% |
| 2011 | 904.92 | 16.84% |
| 2010 | 774.50 | 5.21% |
| 2009 | 736.15 | 44.58% |
| 2008 | 509.16 | -5.10% |
| 2007 | 536.55 | -47.01% |
| 2006 | 1.01K | -20.35% |
| 2005 | 1.27K | -92.50% |
| 2004 | 16.95K | -1,717.69% |
| 2003 | -1.05K | 452.87% |
| 2002 | -189.50 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -335.44% |
US
|
|
| -28.36 | 131.97% |
US
|
|
| -24.57 | 100.96% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -348.10% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.